Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 17, 2007, Pages 4901-4905

  Ray, Nicholas C ^a   Clark, Robin D ^b   Clark, David E ^a   Williams, Karen ^a   Hickin, H G ^a   Crackett, Peter H ^a   Dyke, Hazel J ^a   Lockey, Peter M ^a   Wong, Melanie ^a   Devos, René ^a   White, Anne ^a   Belanoff, Joseph K ^b  

^a Argenta Discovery Ltd   (United Kingdom)

^b Corcept Therapeutics Inc ^*  (United States)

Author keywords

Antagonist; Depression; Glucocorticoid; Psychotic

Indexed keywords

CP 409069; GLUCOCORTICOID RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; RU 43044; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; IN VIVO STUDY; NONHUMAN; RAT; THREE DIMENSIONAL IMAGING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GLUCOCORTICOIDS; HUMANS; KINETICS; MODELS, CHEMICAL; MOLECULAR CONFORMATION; RATS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, STEROID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34547552521     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.06.036     Document Type: Article

References (12)

1. For descriptions of the classification and etiology of depressive diseases, see (a) Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. (DSM-IV), American Psychiatric Association, 2000.
2. Sadock B., and Sadock V. Kaplan and Sadock's Synopsis of Psychiatry (2002), Williams and Wilkins, Lippincott
3. Schatzberg A.F., and Rothschild A.J. Am. J. Psychiatry 149 (1992) 733
4. Belanoff J.K., Kalehzan M., Sund B., Fleming Ficek S.K., and Schatzberg A.F. Am. J. Psychiatry 158 (2001) 1612
5. Belanoff J.K., Rothschild A.J., Cassidy F., DeBattista C., Baulieu E.-E., Schold C., and Schatzberg A.F. Biol. Psychiatry 52 (2002) 386
6. DeBattista C., Belanoff J., Glass S., Kahn A., Horne R.L., Blasey C., Carpenter L.L., and Alva G. Biol. Psychiatry 60 (2006) 1343
7. Lemmen C., Lengauer T., and Klebe G. J. Med. Chem. 41 (1998) 4502. http://www.biosolveit.de FlexS is developed and distributed by BioSolveIT GmbH. http://www.biosolveit.de
8. Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., Chang G., Hendrickson T., and Still W.C. J. Comput. Chem. 11 (1990) 440
9. Developed and distributed by Daylight Chemical Information Systems, Inc. http://www.daylight.com.
10. Morgan B.P., Swick A.G., Hargrove D.M., LaFlamme J.A., Moynihan M.S., Carroll R.S., Martin K.A., Lee E., Decosta D., and Bordner J. J. Med. Chem. 45 (2002) 2417
11. 3H]progesterone, Pan Vera 24900 PR.
12. For a recent review of non-steroidal GR antagonists, see. Mohler M.L., He Y., Wu Z., Hong S.S., and Miller D.D. Expert Opin. Ther. Patents 17 (2007) 59